Moneycontrol
HomeNewsBusinessStocksIpca Laboratories share price falls 2.01%; among top losers on Nifty Midcap 150
Trending Topics

Ipca Laboratories share price falls 2.01%; among top losers on Nifty Midcap 150

With the stock's last traded price at Rs 1,349, Ipca Laboratories is currently trading lower in today's session.

August 13, 2025 / 11:35 IST
Story continues below Advertisement
Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Ipca Laboratories shares declined by 2.01% to Rs 1,349 in Wednesday's session and the stock is among the top losers on Nifty Midcap 150. At 11:24 am, the stock traded lower compared to its previous close.

Financial Overview

Story continues below Advertisement

The following tables provide a consolidated overview of Ipca Laboratories' financial performance, including quarterly and annual data for revenue, net profit, and key financial ratios.

Consolidated Quarterly Results

HeadingJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
RevenueRs 2,092.63 CroreRs 2,354.90 CroreRs 2,245.37 CroreRs 2,246.69 CroreRs 2,308.85 Crore
Net ProfitRs 198.98 CroreRs 245.44 CroreRs 277.33 CroreRs 65.78 CroreRs 234.42 Crore
EPS7.589.059.782.679.19

The revenue for the quarter ending June 2025 was Rs 2,308.85 Crore, up from Rs 2,092.63 Crore in June 2024. The net profit for the quarter ending June 2025 was Rs 234.42 Crore, compared to Rs 198.98 Crore in the same quarter of the previous year.

Consolidated Annual Results

Heading20212022202320242025
RevenueRs 5,419.99 CroreRs 5,829.79 CroreRs 6,244.32 CroreRs 7,705.04 CroreRs 8,939.59 Crore
Net ProfitRs 1,148.84 CroreRs 910.95 CroreRs 491.93 CroreRs 529.21 CroreRs 787.53 Crore
EPS45.0134.8518.5825.8235.14
BVPS371.79219.51233.16304.57273.88
ROE24.2416.098.068.6410.61
Debt to Equity0.050.140.250.220.19

The annual revenue for 2025 was Rs 8,939.59 Crore, up from Rs 7,705.04 Crore in 2024. The net profit for 2025 was Rs 787.53 Crore, compared to Rs 529.21 Crore in the previous year.

Consolidated Yearly Income Statement

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
SalesRs 8,939 CroreRs 7,705 CroreRs 6,244 CroreRs 5,829 CroreRs 5,419 Crore
Other IncomeRs 92 CroreRs 124 CroreRs 125 CroreRs 66 CroreRs 62 Crore
Total IncomeRs 9,032 CroreRs 7,829 CroreRs 6,369 CroreRs 5,896 CroreRs 5,482 Crore
Total ExpenditureRs 7,816 CroreRs 6,848 CroreRs 5,579 CroreRs 4,752 CroreRs 4,084 Crore
EBITRs 1,216 CroreRs 980 CroreRs 790 CroreRs 1,143 CroreRs 1,398 Crore
InterestRs 84 CroreRs 138 CroreRs 45 CroreRs 7 CroreRs 9 Crore
TaxRs 343 CroreRs 313 CroreRs 253 CroreRs 224 CroreRs 240 Crore
Net ProfitRs 787 CroreRs 529 CroreRs 491 CroreRs 910 CroreRs 1,148 Crore

The sales increased from Rs 7,705 Crore in March 2024 to Rs 8,939 Crore in March 2025. Net profit also increased from Rs 529 Crore in March 2024 to Rs 787 Crore in March 2025.

Consolidated Quarterly Income Statement

Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
SalesRs 2,308 CroreRs 2,246 CroreRs 2,245 CroreRs 2,354 CroreRs 2,092 Crore
Other IncomeRs 32 CroreRs 25 CroreRs 20 CroreRs 26 CroreRs 20 Crore
Total IncomeRs 2,341 CroreRs 2,272 CroreRs 2,265 CroreRs 2,381 CroreRs 2,113 Crore
Total ExpenditureRs 1,992 CroreRs 2,123 CroreRs 1,880 CroreRs 2,013 CroreRs 1,798 Crore
EBITRs 349 CroreRs 149 CroreRs 384 CroreRs 367 CroreRs 314 Crore
InterestRs 18 CroreRs 21 CroreRs 16 CroreRs 22 CroreRs 24 Crore
TaxRs 96 CroreRs 62 CroreRs 90 CroreRs 99 CroreRs 91 Crore
Net ProfitRs 234 CroreRs 65 CroreRs 277 CroreRs 245 CroreRs 198 Crore

The sales increased from Rs 2,092 Crore in June 2024 to Rs 2,308 Crore in June 2025. Net profit also increased from Rs 198 Crore in June 2024 to Rs 234 Crore in June 2025.

Cash Flow

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Operating ActivitiesRs 1,321 CroreRs 944 CroreRs 805 CroreRs 856 CroreRs 1,090 Crore
Investing ActivitiesRs -869 CroreRs -1,291 CroreRs -725 CroreRs -855 CroreRs -520 Crore
Financing ActivitiesRs -282 CroreRs -552 CroreRs 507 CroreRs 426 CroreRs -305 Crore
OthersRs 0 CroreRs 76 CroreRs 0 CroreRs 4 CroreRs 0 Crore
Net Cash FlowRs 168 CroreRs -823 CroreRs 588 CroreRs 431 CroreRs 263 Crore
Balance Sheet
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Share CapitalRs 25 CroreRs 25 CroreRs 25 CroreRs 25 CroreRs 25 Crore
Reserves & SurplusRs 6,923 CroreRs 6,306 CroreRs 5,816 CroreRs 5,466 CroreRs 4,676 Crore
Current LiabilitiesRs 2,386 CroreRs 2,355 CroreRs 1,805 CroreRs 1,465 CroreRs 1,160 Crore
Other LiabilitiesRs 2,425 CroreRs 2,413 CroreRs 978 CroreRs 681 CroreRs 206 Crore
Total LiabilitiesRs 11,760 CroreRs 11,101 CroreRs 8,626 CroreRs 7,638 CroreRs 6,068 Crore
Fixed AssetsRs 4,798 CroreRs 4,805 CroreRs 2,853 CroreRs 2,669 CroreRs 2,260 Crore
Current AssetsRs 6,268 CroreRs 5,538 CroreRs 5,189 CroreRs 4,457 CroreRs 3,436 Crore
Other AssetsRs 694 CroreRs 756 CroreRs 583 CroreRs 511 CroreRs 370 Crore
Total AssetsRs 11,760 CroreRs 11,101 CroreRs 8,626 CroreRs 7,638 CroreRs 6,068 Crore
Contingent LiabilitiesRs 613 CroreRs 303 CroreRs 2,125 CroreRs 274 CroreRs 369 Crore
Financial Ratios
RatioMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Basic EPS (Rs.)45.0134.8518.5825.8235.14
Diluted EPS (Rs.)45.0134.8518.5821.5729.08
Book Value /Share (Rs.)371.79219.51233.16304.57273.88
Dividend/Share (Rs.)8.004.004.004.004.00
Face Value21111
Gross Profit Margin (%)29.6523.5916.8518.7620.34
Operating Margin (%)25.7919.6112.6614.1215.89
Net Profit Margin (%)21.1915.627.876.868.80
Return on Networth / Equity (%)24.2416.098.068.6410.61
ROCE (%)28.4818.5211.5912.4415.15
Return On Assets (%)18.7811.575.464.936.27
Current Ratio (X)2.963.042.872.352.63
Quick Ratio (X)1.591.771.911.301.55
Debt to Equity (x)0.050.140.250.220.19
Interest Coverage Ratios (X)177.79178.9123.1110.4621.42
Asset Turnover Ratio (%)0.910.800.770.780.78
Inventory Turnover Ratio (X)1.100.960.951.053.55
3 Yr CAGR Sales (%)28.9924.3015.9019.2323.83
3 Yr CAGR Net Profit (%)117.1443.23-10.30-32.13-7.02
P/E (x)21.1530.5843.6147.9242.74
P/B (x)5.134.903.524.965.48
EV/EBITDA (x)14.9619.7319.2323.4522.26
P/S (x)4.454.623.294.084.26
Corporate Actions

Ipca Laboratories has announced several corporate actions, including dividend payouts and a stock split.

Dividends:

Bonus History: Stock Splits:
Ipca Laboratories had its Annual General Meeting on August 11, 2025, with the scrutinizer's report submitted to the exchange on August 12, 2025. An audio link for the conference call held on August 12, 2025, is also available.